retatrutide parkinson's disease trial nct The NADPARK study: A randomized phase I of nicotinamide riboside supplementation in Quarterly Drug Pipeline: July 2024

Brain Sci 13:1503 Arillotta D, Floresta G, Papanti Pelletier GD et al (2024) Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach

Retatrutide (LY-3437943) is a synthetic 39-amino-acid peptide developed as a triple agonist of the GLP-1, GIP and glucagon receptors

10.1007/s00125-016-4179-x 14

This ensures that as your appetite decreases, the quality of your nutrition increases, preventing the fatigue and muscle loss often associated with unmonitored GLP-1 use

Design Defects: The drugs may be inherently dangerous due to how they interact with the bodys natural digestive and vascular systems